These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28928270)

  • 1. The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy.
    Calabrese L; Mariette X
    Ann Rheum Dis; 2018 Feb; 77(2):162-164. PubMed ID: 28928270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunopathogenesis of rheumatic immune adverse events from checkpoint inhibitors: prospects for targeted therapy.
    Calabrese LH; Calabrese C
    Curr Opin Rheumatol; 2020 Mar; 32(2):175-183. PubMed ID: 31922970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective.
    Steven NM; Fisher BA
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii29-vii39. PubMed ID: 31816079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Sandigursky S; Mor A
    Curr Rheumatol Rep; 2018 Sep; 20(10):65. PubMed ID: 30191417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.
    Abdel-Wahab N; Shah M; Lopez-Olivo MA; Suarez-Almazor ME
    Ann Intern Med; 2018 Jan; 168(2):121-130. PubMed ID: 29297009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.
    Narváez J; Juarez-López P; LLuch J; Narváez JA; Palmero R; García Del Muro X; Nolla JM; Domingo-Domenech E
    Autoimmun Rev; 2018 Oct; 17(10):1040-1045. PubMed ID: 30103042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.
    Leipe J; Mariette X
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii49-vii58. PubMed ID: 31816078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-related dermatologic toxicities: to make a long story short.
    Angelaki A; Lampropoulou DI; Aravantinos G
    Cutan Ocul Toxicol; 2020 Mar; 39(1):10-12. PubMed ID: 31648558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists.
    Pacholczak-Madej R; Kosałka-Węgiel J; Kuszmiersz P; Mituś JW; Püsküllüoğlu M; Grela-Wojewoda A; Korkosz M; Bazan-Socha S
    Int J Environ Res Public Health; 2023 Mar; 20(6):. PubMed ID: 36981837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know?
    Gediz F; Kobak S
    Curr Rheumatol Rev; 2019; 15(3):201-208. PubMed ID: 30659547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune complications of cancer immunotherapy.
    Dhodapkar KM
    Curr Opin Immunol; 2019 Dec; 61():54-59. PubMed ID: 31557690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rheumatological Adverse Events of Cancer Therapy with Immune Checkpoint Inhibitors.
    Cano-Cruz LG; Barrera-Vargas A; Mateos-Soria A; Soto-Perez-de-Celis E; Merayo-Chalico J
    Arch Med Res; 2022 Feb; 53(2):113-121. PubMed ID: 34649738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rheumatic immune-related adverse events from cancer immunotherapy.
    Calabrese LH; Calabrese C; Cappelli LC
    Nat Rev Rheumatol; 2018 Oct; 14(10):569-579. PubMed ID: 30171203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?
    Kostine M; Cappelli LC; Calabrese C; Calabrese LH; Bingham CO; Richez C; Gottenberg JE; Lambotte O
    Ann Rheum Dis; 2019 Jun; 78(6):860-862. PubMed ID: 30659050
    [No Abstract]   [Full Text] [Related]  

  • 16. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge.
    Kostine M; Chiche L; Lazaro E; Halfon P; Charpin C; Arniaud D; Retornaz F; Blanco P; Jourde-Chiche N; Richez C; Stavris C
    Rev Med Interne; 2017 Aug; 38(8):513-525. PubMed ID: 28214182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors.
    Tocut M; Brenner R; Zandman-Goddard G
    Autoimmun Rev; 2018 Jun; 17(6):610-616. PubMed ID: 29631064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rheumatic complications in cancer patients treated with immune checkpoint inhibitors.
    Lee KA; Kim HR; Yoon SY
    Korean J Intern Med; 2019 Nov; 34(6):1197-1209. PubMed ID: 31014065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical management of rheumatic immune-related adverse events : Recognize and treat rheumatological side effects of checkpoint inhibition].
    Benesova K; Leipe J
    Z Rheumatol; 2020 Aug; 79(6):545-553. PubMed ID: 32613268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
    Thompson JA; Schneider BJ; Brahmer J; Andrews S; Armand P; Bhatia S; Budde LE; Costa L; Davies M; Dunnington D; Ernstoff MS; Frigault M; Kaffenberger BH; Lunning M; McGettigan S; McPherson J; Mohindra NA; Naidoo J; Olszanski AJ; Oluwole O; Patel SP; Pennell N; Reddy S; Ryder M; Santomasso B; Shofer S; Sosman JA; Wang Y; Weight RM; Johnson-Chilla A; Zuccarino-Catania G; Engh A
    J Natl Compr Canc Netw; 2020 Mar; 18(3):230-241. PubMed ID: 32135517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.